Tinostamustine for use in treating sarcoma
AssigneePurdue Pharma L.P.
InventorThomas Jorg Mehrling
Life of this patent
Estimating the term…
Abstract
There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma in a patient in need thereof.
Claims16
Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma in a patient in need thereof selected from soft tissue sarcoma, bone sarcoma or non-KIT gastrointestinal stromal tumour (GIST).
Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma according to any preceding claim, wherein the cancer is relapsed and/or refractory.
Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma according to any preceding claim, wherein tinostamustine or a pharmaceutically acceptable salt thereof is administered intravenously to the patient in need thereof at a dosage level of from 0.3 to 300 mg/m2 body surface area of the patient, of from 60 to 150 mg/m2 body surface area of the patient, or of from 80 to 100 mg/m2 body surface area of the patient.
A kit comprising tinostamustine or a pharmaceutically acceptable salt thereof together with instructions for treating sarcoma selected from soft tissue sarcoma, bone sarcoma or non-KIT gastrointestinal stromal tumour (GIST).
Dependencies are inferred from the claim text.